AVITA Medical, Inc. Form 8-K Summary
Business context and reporting period
This Form 8-K, filed September 30, 2022, reports executive leadership changes effective September 28, 2022. The report’s earliest event date is September 26, 2022. AVITA Medical is a Delaware-incorporated medical technology company whose common stock trades on Nasdaq under the symbol RCEL.
Key financial metrics
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other operating or financial metrics. It is focused on management changes and related employment arrangements.
Material changes versus the prior comparable period
- The Board terminated Dr. Michael Perry as President and Chief Executive Officer, effective September 28, 2022. Dr. Perry remains a director.
- James Corbett was appointed President and Chief Executive Officer, effective September 28, 2022. He had served as a non-executive director since July 2021.
- Mr. Corbett brings approximately 40 years of medical-device leadership experience, including service as CEO of CathWorks Ltd. and three publicly listed companies.
Compensation, outlook, risks, and unusual items
- Mr. Corbett’s employment agreement provides for an initial three-year term, with automatic one-year extensions absent timely termination notice.
- Annual base salary is $600,000, subject to annual review.
- Annual target bonus opportunity is 60% of base salary, with a stated range from 0% to 200% of base salary based on individual and Company performance goals determined by the Board.
- Mr. Corbett received a stock-option grant valued at $1,000,000 on September 28, 2022, subject to stockholder approval. The options vest in equal annual installments over four years, beginning after the first year of service.
- The agreement includes customary retirement, medical, benefit, and vacation provisions. The Company may terminate employment without cause upon written notice and payment of amounts owed.
- The filing does not provide financial guidance or a broader business outlook. It also does not disclose severance or other termination payments for Dr. Perry.
Important facts for investors to verify
- Confirm stockholder approval requirements and final terms of the $1,000,000 option grant.
- Review the complete employment agreement for termination, severance, change-in-control, and other compensation provisions.
- Assess the potential financial impact of the new CEO’s salary, bonus opportunity, equity compensation, and related accounting expense.
- Review subsequent filings for additional information regarding Dr. Perry’s director status and any further leadership or governance changes.